OPIOID CRISIS V2:
AMERICA’S TOP MEDIA AND MEDICAL INSTITUTIONS SPIN LETHAL PUBLIC HEALTH DISINFORMATION
This time from disconfirming results for their endorsement of vaping as harm reduction
by Clark Miller
Published April 10, 2019
Updated April 12, 2021
that America’s Premier Medical Research Journal, the Journal of the American Medical Association (JAMA) – whose endorsed use of e-cigarettes, “vaping”, as a form of “harm reduction” has become within months a child substance use epidemic – would naturally help disseminate research conclusions that generate predictable risk of continued illness and mortality by overtly falsely attributing quit smoking success rates of 10 percent and 18 percent to nicotine replacement therapy (NRT) and use of e-cigarettes, respectively.
Success rates of greater than 0 percent (greater than no effectiveness) are not supported by the uncontrolled study results, from analysis based on the most elementary principles and errors of research design and interpretation – comparison to control; internal validity; and external validity.
And predictable that those mortality-predicting unsupported conclusions would emanate from a published report in the New England Journal of Medicine (NEJM) – the very journal portraying as significant the clinically meaningless “research” report used to justify runaway, medically inappropriate prescription of opioids that would fuel America’s lethal opioid epidemic.
And that, just as in the craven, grossly negligent, and malfeasant mix of criminal behavior, group think, and institutional pathology generating the opioid crisis, mass and social media would be along for the ride.
From America’s Premier medical research journal:
e-Cigarettes were more effective for smoking cessation than nicotine replacement therapy in combination with behavioral support, found a study in the New England Journal of Medicine.
A recent study suggests e-cigarettes were more effective for smoking cessation than nicotine replacement therapy.
The 886 participants attending UK National Health Service stop-smoking services were randomly assigned to receive a 3-month supply of their preferred nicotine replacement products, or to an e-cigarette starter pack. Both groups received weekly one-on-one behavioral support for at least 4 weeks.
The 1-year abstinence rate, which was validated biochemically, was 18.0% in the e-cigarette group compared with 9.9% in the nicotine replacement group. Among those who quit, 80% of participants in the e-cigarette group vs 9% of those in the nicotine replacement group continued to use the nicotine products. Although long-term e-cigarette use may present harms, it may also prevent smoking relapse, wrote the authors.
But there are problems with the NEJM study,
violations of the most important and elementary of errors in research design and interpretation. Problems that on critical analysis of the research contextualized in the relevant bodies and science and associated research in this post, establish that the NEJM study points to a lack of any benefit for smoking cessation attributable to NRT or e-cigarettes, in contrast to the heralded and widely disseminated assurances, spreading through mass and social media, that the “treatments” were effective with 10% and 18% success rates, respectively.
Below and here: how the mass and social media broadcast of lethal public health misinformation went down
Violations of the most basic and elementary requirements for research design and interpretation – violations of the type required to fabricate beneficial effects for smoking cessation from the NEJM study comparing NRT to vaping -were deconstructed in recent posts –
Grossly incompetent media reporting on research related to public health crises continues to expose vulnerable Americans to potentially lethal misinformation. Despite mounting mortality, public health, and social costs, there is no evidence of accountability, correction, or adaptive use of the overt failure of media watchdog and evaluative roles that helped fuel the lethal opioid crisis – a collaboration, as exposed here, in reporting by Sam Quinones in “Dreamland”, of medical, academic, research, and media institutions to market fabrications driving prescription of addictive opioids for common chronic pain, a non-medical condition, without evidence supporting effectiveness or safety.
Nothing has changed. In a recent egregious example, writers at Vox, the New York Times, other outlets in ignorance of the most basic of research interpretation errors promoted entirely unsupported conclusions promoting false confidence in effectiveness of use of electronic cigarettes or nicotine replacement therapy (NRT) products as treatments for the highly lethal condition of compulsive use of tobacco by smoking. As in the media/pharma/medical industry collaboration that created the lethal opioid crisis, significant harm is predicted by the distortions and false messaging, by promotion of false confidence in unsupported treatments for smoking. The harms include tobacco-related mortality and morbidity that eclipse that related to other drugs, and harms due to smoking linked to incidence of chronic pain syndromes and exacerbated pain perception, both factors driving opioid misuse and the opioid crisis.
To describe adequately and accurately the extent to which American media distort, misreport and mislead vulnerable Americans on the life-and-death issues tied to opioid and other lethal substance use epidemics is a simple matter – as explained here, essentially all reporting is defined and driven by the useful constructed fictions required to support the industries and institutions that gain by using public healthcare resources to fuel worsening crises – just as in the media-medical industry-pharmaceutical-academic-healthcare institution collaboration that lied to America about common chronic pain and opioids to create the opioid crisis. Those fictions usefully rationalize, support and perpetuate practices that instead of providing evidence-based and effective prevention and treatment for the complex behavior of compulsive substance use (“addiction”), are established by longstanding evidence to predict harm or at best no benefit.
Predictably, the sham “treatments” that drive profits and entitlement systems generate and perpetuate lethal epidemics, lacking effectiveness for the health conditions vulnerable and trusting Americans trapped in epidemics are assured – by medical experts and media – they are effective treatments for.
Recent examples of reporting on health-related research are egregious and illustrative. Unsupported and potentially lethal conclusions constructed in ignorance of the most elementary pitfalls of research interpretation and analysis are consumed with knowing assent and approval by research-illiterate media and social media popularizers of fictions required to maintain status and cultural capital for health industries served.
This Vox report on an uncontrolled research study comparing vaping to nicotine replacement therapy (NRT) for smoking cessation headlined the study as a “control” (sic) trial. But there was no control (= no treatment) group, critically and importantly determining limits of interpretation and effectiveness of treatment (vaping and NRT) effects for a potentially lethal condition that claims around a half million American lives each year, among other costs including contributing to the opioid crisis.
“Do e-cigarettes actually help smokers quit? Now, the first, large rigorous assessment offers an unequivocal answer: yes.”, asserting that smokers can expect cessation success rates by use of NRT and e-cigs of “18 percent among the e-cigarette group, compared to 9.9 percent among those using traditional nicotine replacement therapy”
That authoritative assurance, disseminated of course via social media, going “viral”.
Accurate interpretation and reporting to a public vulnerable to the harms of smoking – deaths and other harms that eclipse those of opioids, methamphetamine, and alcohol combined – is particularly important because of the lethality of compulsive tobacco use, the public health and social costs, and contribution to other public health problems . . .
like the opioid crisis.
What does the research say about tobacco use, chronic pain as related to the opioid crisis, and how public healthcare funds should be effectively used to support tobacco cessation ?
Extensive research supports the role of tobacco use in etiology (cause) of chronic pain conditions including fibromyalgia, lower back pain, rheumatoid arthritis and in exacerbated perception of chronic pain(1)
Additional research points to increasing risk of continued or return to problem use of substances including opioids due to tobacco use – acting as a “gateway drug” for opioids (2-4)
Recognition of the research-based links among tobacco use, chronic pain, and problem opioid use has led progressive, evidence-based programs to begin making tobacco cessation services a key component of addressing the opioid crisis(2,4)
2. Pakhale S, Kaur T, Charron C, et al. Management and Point-of-Care for Tobacco Dependence (PROMPT): a feasibility mixed methods community-based participatory action research project in Ottawa, Canada BMJ Open 2018;8
Maybe we should take a look
Research and Experimental Design and Interpretation 101
The randomized controlled trial (RCT) is an aspirational standard for design of research studies to allow, ideally, confident conclusions to be drawn about whether a treatment factor is effective, for example, in stopping, preventing, or reversing a health condition – potentially answering, with replication, the critically important question Does it work? Can this treatment be confidently expected to help, to prevent harm or death, regain health and functioning?
The “controlled” element is critically important and often failed in design. In an adequately designed and implemented RCT, a control or “no treatment” group ideally is exposed to, experiences, the very same circumstances as the “experimental” or “treatment” group receiving the treatment (e.g. medication, therapy) being evaluated for effectiveness – with the sole difference of not receiving the treatment. A treatment can be confidently concluded to be effective, helpful (versus ineffective or harmful) only if there are significantly more positive outcomes for the treatment group than for subjects in the control group, who may have positive outcomes due to, for example, the passing of time, spontaneous remission, placebo effect, other unidentified factors occurring over the course of a clinical trial.
There is no possibility of confidently attributing treatment, or curative, benefit to an evaluated treatment (e.g. pill, procedure) without comparison to an adequately designed control group. That requirement and potential (and potentially lethal) error in experimental design and interpretation is among the most elementary and important.
In the case of the recent study widely cited in popular media and excitedly heralded as providing important results on effectiveness of stop smoking interventions, published in the New England Journal of Medicine (NEJM) – that’s the journal largely responsible for misrepresenting as “research” the unsupported conclusions generating waves of fabrications needed to fuel the lethal opioid crisis – there was no control group, instead a comparison of two treatment groups: subjects using e-cigarettes to assist in tobacco smoking cessation, and subjects using nicotine replacement therapy (NRT).
That’s not true. Another lethally confounding factor in this study was that there were no usefully designed treatment groups instead there was another, second, type of cessation intervention applied concurrently to each of those treatment groups – an intervention established to independently provide tobacco cessation benefit compared to actual control groups in adequately designed studies – and that confounding effect also intractably prevented attributing the ascribed and celebrated benefit to either NRT or use of e-cigarettes in conjunction with failure to evaluate external validity of the study. But more about that below.
What was widely reported, celebrated, and messaged to a tobacco smoking pubic at risk of death without effective guidance and treatments in support of cessation (in addition to the overtly erroneous description of the study as a “control” trial) are claims that based on measured outcomes (smokers still not smoking a year later), NRT had a smoking cessation effectiveness of 10%, vaping 18%.
“A seminal study”
The success rate was still low — 18 percent among the e-cigarette group, compared to 9.9 percent among those using traditional nicotine replacement therapy — but many researchers who study tobacco and nicotine said it gave them the clear evidence they had been looking for.
“This is a seminal study,” said Dr. Neal L. Benowitz, chief of clinical pharmacology at the University of California, San Francisco, an expert in nicotine absorption and tobacco-related illnesses, who was not involved in the project. “It is so important to the field.”
Let’s consider those claims, in the context of the most elementary principles of research design and interpretation including the control group, the treatment group, and external validity.
No Control group
In the study published in the prestigious medical research journal NEJM, there was no control group. What does that matter?
As established in multiple large scale epidemiological surveys with large sample sizes, consistently a majority of individuals with tobacco use disorder (the “disease” of tobacco smoking), as well as for alcohol, methamphetamine, cannabis, and opioid use disorders are found to stop using those substances and not return to use, most often stopping without any forms of treatment or formal support – they just quit.
Accordingly, in any clinical trial it is expected that some significant portion of subjects in control (no treatment or placebo) groups will have positive outcomes – that is, they will stop use of the substance without receiving the evaluated treatment – MEANING: that portion of the subjects in the treatment group measured positive outcomes DON’T COUNT. They would have had positive outcomes without the treatment, and those cases cannot be attributed to the treatment.
That’s why, in meaningfully designed studies, results are framed as, “Compared to control group . . .” or a statistical probability value (P) or 95% confidence interval for success values for subjects receiving the experimental treatment versus subject in control group – allowing confident conclusions about whether there is any benefit attributable to the treatment.
In this Veterans Administration (VA) summary of research on smoking intervention trials, success rates for control groups (no treatment or placebo) tend to range approximately from 10 to 14%.
To repeat: in controlled clinical trials smoking cessation success for control (no treatment) groups tends to range approximately from 10 to 14%.
Do the math.
It’s important to note that that summary would have included trials for which outcomes were measured over shorter follow-up periods than the one year in the NEJM study.
So, it seems crucial
in order to protect vulnerable Americans from the type of lethal medical misinformation that, for example, creates an opioid crisis, to consider the most important and elementary aspects of experimental design and interpretation that are critical to preventing misinformation.
The most current research on effectiveness of NRT, in controlled studies, establishes that benefit attributable to the effects of the NRT intervention range from clinically insignificant (negligible) to no benefit.
Research and Experimental Design and Interpretation 102
There are many ways that research – especially when interpreted by professionals and writers out of scope of competence to analyze and think critically about research results, that is, without training or experience as researchers – can be distorted, invalid, with illegitimately drawn conclusions and potentially lethal consequences One of those ways is related to the distinction between statistical significance and clinical significance.
Statistical significance refers to the method – essentially the purpose and value of statistical testing – by which a probability value (for example P=.02) represents the confidence of drawing the conclusion of a true (not due to chance in the experiment) benefit, or difference between treatment and no treatment as indicated by the chosen measure for a difference. A probability value of P=.02, for example, would indicate the likelihood of the measured difference not being “real” as only 2%, so we would have relatively high confidence in it being a real difference. It does not tell us about the magnitude of the difference or whether the difference can reasonable be expected to be gained by smokers under realistic natural conditions in their natural settings (“external validity”).
Those magnitudes, or size of benefit, for Nicotine Replacement Therapy (NRT) when treatment results in a statistically significant difference, and for the other medications, are quite small, for example in this study a benefit to 3%, or 3 of every 100 people treated with NRT. Clinical significance typically in these studies is ignored, masked by focus on the statistical measures like odds ratios, confidence intervals, probability (P) values.
If a statistically significant clinical trial outcome established benefit from a type of chemotherapy for cancer for 3% or 5% of treated patients, would the treatment be recommended and provided to patients? And paid for using public healthcare funds? Or instead would recommendations be to use other treatments with greater clinical significance and to factor quality of life and negative side effects of the treatment into decision-making and recommendations
Apart from the cost in public funds to provide “treatments” for smoking cessation with benefit to only 3 – 5% of patients treated, are there additional costs that would outweigh the very small probability of benefit from the medical-model treatment?
The research related to effectiveness of NRT and other medications for smoking cessation is extensive and can be summarized by main points:
– Effects sizes (clinical significance, or number of patients benefitting from the treatment) have always been small. For example in this study 3% of patients reporting cessation of smoking with NRT.
– Additional studies (5-7) provide evidence of no benefit for smoking cessation from NRT.
5. Stanley, T.D. et al. (2016) Evidence of nicotine replacement’s effectiveness dissolves when meta-regression accommodates multiple sources of bias. Journal of Clinical Epidemiology , Volume 79 , 41 – 45.
7. Herd, N., Borland, R. and Hyland, A. (2009), Predictors of smoking relapse by duration of abstinence: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction, 104: 2088–2099
– Studies routinely combine medication in treatment groups with counseling, the combination typically resulting in more positive outcomes than for the medication alone, and disallowing conclusions about benefit due to the medication alone.
– Individual counseling is effective for smoking cessation, with no indications of lack of benefit, and greater clinical significance than for NRT and medications, one review attributing an increase from 7% success with brief counseling support to 10 – 12% with individual counseling. Those results are for standard counseling for substance use, established as generally ineffective. Use of therapies supported by research and theory as effective would predict larger positive outcomes.
No Treatment Groups either
Nor were there experimentally valid and useful treatment groups in the NEJM study, instead each of the two experimental groups included behavioral health counseling, an intervention established by research to independently predict smoking cessation success in the range of 7 to 12%, as noted.
Predicted cessation success rates due to established effects of smokers quitting on their own, without treatments (in the range of 10 to 14%) and due to behavioral health therapies (7 to 12%) account for cessation rates in both study groups. Only if success rates had significantly exceeded 20% would the hypotheses been suggested – requiring testing in replicated controlled trials – that NRT or use of e-cigarettes provide benefit for smoking cessation.
Testing in replicated randomized controlled trials, with external validity.
And No External Validity
External validity is a feature and measure of the confidence with which a study’s apparent outcomes, under the conditions of the study design, characteristics of subjects, etc., and protocols, can confidently be expected to be realized in natural (community) settings – that is, in the real world where individuals are attempting to stop smoking.
How many smokers switching to e-cigarettes in order to stop smoking likely also engage in evidence-based behavioral health counseling concurrently? >0?
This “seminal” study, widely popularized and celebrated as significant, published in the very medical journal with the key role in normalizing the fabrications generating the lethal opioid crisis, heralded in the NYTimes as establishing an “unequivocal answer: yes” to the question of whether “e-cigarettes actually help smokers quit?” – in fact on evaluation points to a clear lack of evidence supporting effectiveness, the celebratory headlines and media accounts providing medical misinformation to millions of compulsive users of tobacco, a condition with high risk of illness and death.
It is critically important to note that dismantling the fabricated and unsupported conclusions attributing smoking cessation benefit to both NRT and e-cigarettes did not involve a sophisticated analysis of statistical design or other features of the study, instead simply noting the obvious invalidating violations of the most basic and elementary principles of experimental design and interpretation:
– Lack of a control group
– “Treatment” groups that were not meaningful or useful for the hypotheses meant to be evaluated
– Lack of external validity
This is a seminal study,” said Dr. Neal L. Benowitz, chief of clinical pharmacology at the University of California, San Francisco, an expert in nicotine absorption and tobacco-related illnesses, who was not involved in the project. “It is so important to the field.”
The difference between the fabricated outcomes, the fake success rates, versus what is supported, actually established by the results – the basis for a decision to trust and invest in as a cure, a treatment for a life-threatening condition – between an 18% chance of benefit versus zero, or close to zero, is a lot, a big difference, a life-and-death difference.
The NEJM study and its pathologically incompetent and malfeasant interpretation and marketing to a vulnerable population trapped in life-threatening substance use epidemics is a single example, the tip of an iceberg, a symptom of massive underlying institutional and individual diminished capacity for critical thought, competence, integrity and ethical behavior, a predictor of opioid and substance use epidemics, of public harm.
It’s a pathology that creates and runs through allowable, constructed public discourse, the matrix that informs consumers of their options, a matrix managed by and serving forces with the cultural capital to fabricate it.
That deep underlying social and institutional pathology – that generated a predictable, avoidable, for-profit lethal opioid epidemic – has barely been examined, let alone treated. Nothing has changed.
“Crisis is a necessary condition for a questioning of doxa, but is not in itself a sufficient condition for the production of a critical discourse.”
– Pierre Bourdieu Outline of a Theory of Practice (1972)
In Bourdieu’s Theory of Practice, heterodoxy is dissent, challenge to what “goes without saying” – the accepted, constructed doxa, “knowledge”, reality, that goes without saying precisely because it “comes without saying”, without real scrutiny, untested, unquestioned. The function of doxa is not knowledge or truth or promotion of the collective good, but to protect and serve the interests of those with the power, the cultural capital, to create it.